569 related articles for article (PubMed ID: 31494202)
1. Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.
Zhou H; Peng X; Hou T; Zhao N; Qiu M; Zhang X; Liang X
J Ethnopharmacol; 2020 Jan; 246():112218. PubMed ID: 31494202
[TBL] [Abstract][Full Text] [Related]
2. Label-free cell phenotypic study of opioid receptors and discovery of novel mu opioid ligands from natural products.
Hou T; Xu F; Peng X; Zhou H; Zhang X; Qiu M; Wang J; Liu Y; Liang X
J Ethnopharmacol; 2021 Apr; 270():113872. PubMed ID: 33485984
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
4. Bioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors.
Yang Y; Vyawahare R; Lewis-Bakker M; Clarke HA; Wong AHC; Kotra LP
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751516
[TBL] [Abstract][Full Text] [Related]
5. Development and preliminary validation of a plate-based CB1/CB2 receptor functional assay.
Dossou KS; Devkota KP; Kavanagh PV; Beutler JA; Egan JM; Moaddel R
Anal Biochem; 2013 Jun; 437(2):138-43. PubMed ID: 23481912
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol skews biased agonism at cannabinoid CB
Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
[TBL] [Abstract][Full Text] [Related]
9. Cannabichromene is a cannabinoid CB
Udoh M; Santiago M; Devenish S; McGregor IS; Connor M
Br J Pharmacol; 2019 Dec; 176(23):4537-4547. PubMed ID: 31368508
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
11. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.
Glass M; Felder CC
J Neurosci; 1997 Jul; 17(14):5327-33. PubMed ID: 9204917
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Showalter VM; Compton DR; Martin BR; Abood ME
J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
[TBL] [Abstract][Full Text] [Related]
13. Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-G
Hua T; Li X; Wu L; Iliopoulos-Tsoutsouvas C; Wang Y; Wu M; Shen L; Brust CA; Nikas SP; Song F; Song X; Yuan S; Sun Q; Wu Y; Jiang S; Grim TW; Benchama O; Stahl EL; Zvonok N; Zhao S; Bohn LM; Makriyannis A; Liu ZJ
Cell; 2020 Feb; 180(4):655-665.e18. PubMed ID: 32004463
[TBL] [Abstract][Full Text] [Related]
14. Dynamic mass redistribution as a means to measure and differentiate signaling via opioid and cannabinoid receptors.
Codd EE; Mabus JR; Murray BS; Zhang SP; Flores CM
Assay Drug Dev Technol; 2011 Aug; 9(4):362-72. PubMed ID: 21323580
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
[TBL] [Abstract][Full Text] [Related]
16. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L; Cornett BL; Mackie K; Hohmann AG
Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC; Wright JL; McPartland JM; Tyndall JD
Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
[TBL] [Abstract][Full Text] [Related]
19. Pure Δ
Romano B; Pagano E; Orlando P; Capasso R; Cascio MG; Pertwee R; Marzo VD; Izzo AA; Borrelli F
Pharmacol Res; 2016 Nov; 113(Pt A):199-208. PubMed ID: 27498155
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological actions of cannabinoids.
Pertwee RG
Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]